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Abstract
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Chronic elevation of plasma free fatty acid (FFA) levels is commonly associated with obesity,
type 2 diabetes, cardiovascular disease and some cancers. Experimental evidence indicates FFA
and their metabolites contribute to disease development through lipotoxicity. Previously, we
identified a specific fatty acid transport inhibitor CB16.2, a.k.a. Lipofermata, using high
throughput screening methods. In this study, efficacy of transport inhibition was measured in four
cell lines that are models for myocytes (mmC2C12), pancreatic ß-cells (rnINS-1E), intestinal
epithelial cells (hsCaco-2), and hepatocytes (hsHepG2), as well as primary human adipocytes. The
compound was effective in inhibiting uptake with IC50s between 3 and 6 µM for all cell lines
except human adipocytes (39 µM). Inhibition was specific for long and very long chain fatty acids
but had no effect on medium chain fatty acids (C6-C10), which are transported by passive
diffusion. Derivatives of Lipofermata were evaluated to understand structural contributions to
activity. Lipofermata prevented palmitate-mediated oxidative stress, induction of BiP and CHOP,
and cell death in a dose-dependent manner in hsHepG2 and rnINS-1E cells, suggesting it will
prevent induction of fatty acid-mediated cell death pathways and lipotoxic disease by channeling
excess fatty acids to adipose tissue and away from liver and pancreas. Importantly, mice dosed
orally with Lipofermata were not able to absorb 13C-oleate demonstrating utility as an inhibitor of
fatty acid absorption from the gut.
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1. Introduction
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Long-chain fatty acids (LCFAs) are vital dietary components and contribute to normal
metabolic homeostasis including, for example, energy generation and storage, plasma
membrane synthesis, and protein anchoring. Excess free fatty acids (FFA) are esterified and
stored as triglycerides in lipid droplets in various cell types. These subcellular compartments
are dynamic and stored fatty acids can be mobilized by the actions of cellular lipases in a
process regulated by hormones and by proteins associated with the droplets. Apart from
adipocytes, most cells have a limited capacity for lipid storage and when this capacity is
exceeded, cell death may result from a process called lipotoxicity [1–3]. Current evidence
indicates free fatty acids and/or their metabolites mediate cell death [2, 4, 5]. Chronic
imbalances in lipid flux and metabolism often cause a variety of metabolic abnormalities
and pathologies, including hyperlipidemia, type 2 diabetes mellitus (T2D), nonalcoholic
fatty liver disease (NAFLD), heart disease, and some cancers [6–8]. Obesity is a common
initiating condition for these diseases due to chronic hyperlipidemia and elevated free fatty
acids. Lipid overload in pancreatic [β-cells may lead to dysregulated insulin secretion and
apoptotic cell death, both of which may contribute to the genesis of the diabetic state [9, 10].
Lipoapoptosis is also observed in the heart and contributes to the development of heart
failure [11–13]. In liver, chronically elevated fat results in a condition called non-alcoholic
fatty liver disease (NAFLD) that can lead to steatohepatitis (NASH) and eventually to
nonreversible cirrhosis [14, 15]. Therefore, there is much interest in preventing lipotoxicity
that leads to metabolic dysfunction and disease.
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The uptake of unesterified LCFAs into mammalian cells may occur either through passive
diffusion or protein-mediated mechanisms [16–18]. Passive diffusion is operable in all cell
types and is limited by the membrane composition, the ability of the fatty acid to flip from
one side of the membrane to the other, and the presence of intracellular proteins that bind
and extract the fatty acid from the membrane (e.g. FABP or acyl-CoA synthetase (Acs)).
Cells and organs that are specialized in lipid metabolic processes also express proteins
involved in transport of long- and very-long chain fatty acids, which are diffusion limited.
Most information on protein-mediated fatty acid transport has been acquired for adipose
tissue [19, 20], intestine [21], liver [22, 23], and heart [24, 25]. Specific membrane proteins
that increase the uptake of LCFAs when overexpressed in cultured mammalian cells have
been identified. The most prominent and best characterized of these are fatty acid
translocase (FAT)/CD36 [22], the fatty acid transport proteins (FATPs) [26, 27] and longchain fatty acyl-coenzyme A synthetase (Acsl) [16, 28, 29].
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The FATPs are bifunctional proteins, which transport long chain fatty acids (LCFA) into
cells and activate very long chain fatty acids (VLCFA) by esterification with coenzyme A
[30]. The recent characterizations of FATP deletion (KO) and transgenic mouse strains, as
well as data gained from human subjects have clearly demonstrated that FATPs are
important determinants of lipid distribution among different organs and can dynamically
change LCFA uptake in response to altered nutrient availability [24, 31–33]. Recently,
several FATP-specific fatty acid transport inhibitors were selected in a high throughput
screen against human FATP2b, a splice variant that is deficient in VLCFA activation but
that retains LCFA transport activity [34]. Among the hits, CB16.2 (5’-bromo-5-phenyl-
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spiro[3H-1,3,4-thiadiazole-2,3’-indoline]-2’-one) now called Lipofermata was identified as
a compound that specifically blocked human FATP2-mediated fatty acid uptake without
impacting other cellular functions [34]. Lipofermata inhibits fatty acid uptake into HepG2
and Caco-2 cells (models for human hepatocytes and enterocytes, respectively) with high
specificity and affinity [34]. Both cell lines express FATP2. In contrast, inhibition of fatty
acid uptake by Lipofermata into murine 3T3L1 adipocytes, which do not express FATP2 to
a significant extent, is at least 10-times less effective. This suggests Lipofermata may be a
tractable tool to determine the underlying mechanistic features of FATP-dependent transport
to specifically differentiate between effects on different cell types and organ systems
susceptible to lipotoxicity.
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In the present study, we assessed the potency of Lipofermata to inhibit fatty acid transport
across the intestine in mice and in cell lines that are models for pancreatic ß cells and
myocytes, as well as primary human adipocytes. The compound acts as a non-competitive
inhibitor specific for long and very long chain fatty acids. However, it is ineffective in
inhibiting the uptake of medium chain fatty acids (C6-C10). In mice, the compound
inhibited absorption of oleate labeled with 13C. Importantly, we demonstrate that
Lipofermata specifically prevents cellular dysfunction and death caused by exposure to
saturated fatty acids.

2. Materials and Methods
2.1 Chemicals, reagents, and analytical methods
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Lipofermata/CB16.2 (5-Bromo-5'-phenyl-3'H-spiro [indole-3,2'-[1,3,4] thiadiazol]-2(1H)one) and structurally related compounds were either purchased from ChemBridge
Corporation (San Diego, CA, USA) or was synthesized by the Vanderbilt Specialty
Chemistry Center (Nashville, TN, USA) according to the scheme in Fig. 1. C1-BODIPY-C12
(4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid), BODIPY-FL-C5
(4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Pentanoic Acid) and
BODIPY-FL-C16 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3Hexadecanoic Acid) were purchased from Molecular Probes/Invitrogen (Eugene, OR,
USA). Tyloxapol and 13C-oleate (uniformly labeled) were obtained from Sigma-Aldrich
Chemical (St. Louis, MO, USA).
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For analytical characterization of synthesized compounds, low resolution mass spectra were
obtained on an Agilent 1200 series 6130 mass spectrometer. Analytical thin layer
chromatography was performed on Analtech silica gel GF 250 micron plates (Spectrum
Chemical Mfg. Corp., New Brunswick, NJ). Analytical HPLC was performed on an Agilent
HP1100 (Agilent Technologies, Inc., Santa Clara, CA, USA) with both UV detection at 214
and 254 nm and ELSD followed by LC/MS (J-Sphere80-C18, 3.0 × 50 mm using a 4.1 min
gradient of 5%[0.05%TFA/acetonitrile]:95%[0.05%TFA/H2O] to 100%[0.05%TFA/
acetonitrile]. Preparative RP-HPLC purification was performed on a Gilson preparative UVbased system (Gilson, Inc., Middleton, WI, USA) using a Phenomenex Luna C18 column
(50 × 30 mm I.D., 5 µm) (Phenomenex, Torrance, CA., USA) with an acetonitrile
(unmodified)-water (0.1% TFA) custom gradient. Normal-phase silica gel preparative
purification was performed using an automated Combi-flash companion from ISCO
Biochem Pharmacol. Author manuscript; available in PMC 2016 November 01.

Ahowesso et al.

Page 4

Author Manuscript

(Louisville, KY, USA). Solvents for extraction, washing and chromatography were HPLC
grade. All reagents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO,
USA) and were used without purification.
2.2 Synthesis of Lipofermata analogues and characterization of synthesized compounds
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The synthetic route used to prepare CB16.2 (5-Bromo-5'-phenyl-3'H-spiro [indole-3,2'[1,3,4] thiadiazol]-2(1H)-one) analogues is presented in Fig. 1. Briefly, benzothiohydrazide,
B, was prepared according to literature ([35, 36] and references therein) starting from
bromobenzene in a four step two-pot procedure. Initial phenylmagnesium bromide
formation followed by treatment with carbon disulfide and alkylation with chloroacetic acid
afforded S-(thiobenzoyl)-thioglycolic acid intermediate A in good overall yield as described
[36]. Preparation of thiobenzhydrazide B: To a 1 M NaOH (20 mL, 1 equiv) solution of A
(4.0 g, 18.8 mmol) was added water (20 mL) and the orange solution cooled in an ice bath.
Hydrazine hydrate (3.4 g, 55%, 3.3 mL, 37.6 mmol) was added dropwise and the reaction
mixture was stirred for 1.5 h. Dilute HCl was added to bring the reaction pH to 5–6 and was
allowed to stir for 1 h while cooled in an ice bath. The product was collected by vacuum
filtration, washed with chilled water, and air-dried. The crude product was subsequently
recrystallized from ethyl acetate/hexane to yield pure benzothiohydrazide B as white crystals
(1.45 g, 51%). For the preparation of spiro-thiadiazoloindolinones CB16.101, CB16.104,
CB16.106, CB16.107, and CB16.108, a 1 dram vial containing respective isatin C (0.22
mmol) and benzothiohydrazide B (40 mg, 0.26 mmol) was added EtOH (2 mL). The mixture
was sealed and heated for 4 hr at 50°C, cooled to room temperature, concentrated, and
purified by RP-HPLC to yield final compounds (yields 10–45%, HPLC purity >98%):
LC/MS (215 nm >98%) CB16.101 m/z = 296.1 [M+H]; CB16.104 m/z = 282.1 [M+H];
CB16.106 m/z = 366.1 [M+H]; CB16.107 m/z = 312.1 [M+H]; CB16.108 m/z = 298.1 [M
+H].
2.3 Cell culture and reagents

Author Manuscript

Caco-2 cells (ATCC, HTB- 37) were maintained in Earl’s minimal essential medium
(MEM) with 20% FBS in a 95% air 5% CO2 atmosphere at 37°C. For growth and
differentiation, the BD Biosciences Intestinal Epithelium Differentiation Media Pack (BD
Biosciences, Franklin Lakes, NJ, USA) was used. Cells were plated in basal seeding
medium at a density of 8 × 104 cells/well on a collagen-coated black/clear 96-well plate (BD
Biosciences). After 72 h in culture, the basal seeding medium was removed and EnteroSTIM medium (Thermo Fisher Scientific, Inc., New York, NY, USA) was added to each
well. Both media contained mito-serum extender. To estimate final cell number for Caco-2
cells and all cell lines listed below, DNA was stained with Hoechst dye and results
compared to a standard curve generated for each line as detailed in the BioTek® application
note FL600 (BioTek, Winooski, VT, USA).
HepG2 cells (ATCC, HB- 8065) were obtained from the American Type Culture Collection
and were cultured according to the supplier’s protocols. The cells were seeded in 96-well
plates at a seeding density of 8 × 104 cells/well.
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INS-1E cells (generously provided by Pierre Maechler, Ph.D., University Medical Center of
Geneva 4, Switzerland) were cultured at 37°C in a humidified atmosphere containing 5%
CO2 in complete medium composed of RPMI 1640 (Thermo Fisher Scientific, Inc.)
supplemented with 5% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 50 µM, 2mercaptoethanol and 10 mM HEPES as described [37]. The maintenance culture was
passaged once a week by gentle trypsinization, and cells were seeded in 96-well black/clear
plates at a density of 0.2 × 106 cells/well and used for experimentation after 96h.
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De-identified human adipocytes (generously provided by Susan K. Fried, Ph.D., Boston
University, School of Medicine) were seeded in 96-well black/clear plates at a density of 1.5
× 104 cells/well and then maintained in modified MEM, Alpha Modification, with LGlutamine, Ribo/Deoxyribonucleosides (HyClone Laboratories, GE Healthcare Life
Sciences, Logan, UT, USA) and 10% FBS. For differentiation into adipocytes, cells were
treated with 0.54 mM 3-isobutyl-1-methylxanthine (IBMX), 0.1µM dexamethasone, 0.5 µM
human insulin, 10mg/ml transferrin, 33 µM biotin, 17 µM pantothenate, 2 nm T3 and 1 µM
rosiglitazone in DMEM and 10% FBS for 48 h as detailed [38]. After 48 h incubation with
differentiation medium, cells were treated with DMEM/F12 1:1, with L-Glutamine without
HEPES (HyClone Laboratories) and 10% FBS supplemented with IBMX and rosiglitazone
alone for 4 days, then the media was changed to differentiation media without IBMX and
rosiglitazone until lipid droplets were obvious upon microscopic examination (up to 6 days).
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C2C12 cells (ATCC, CRL-1772) were maintained in Dulbecco modified Eagle medium
(DMEM) containing 10% fetal bovine serum (FBS) and 2 mM of L-glutamine at 37°C in a
humidified atmosphere of 5% CO2 in air. For differentiation, cells were plated in
differentiation medium (DMEM containing 10% horse serum) at a density of 8 × 104 cells/
well on a black/clear 96-well plate (BD Biosciences) for 96h.
2.4 Measurement of fatty acid uptake in selected cell lines and expression of FATP
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For each cell type, fatty acid transport kinetics were evaluated according to the method
described in Arias-Barrau, et al. [39]. A range of C1-BODIPY-C12 concentrations, as
specified in Fig. 2, were used in a 5 min assay conducted in kinetic mode on a BioTek
Synergy plate reader using Gen5.2 software. Uptake was measured every 5 sec for 5 min
and rates were determined from the linear portion of the curve between 30 and 90 sec. The
substrate was presented to the cells as a complex with fatty acid-free BSA to give BODIPYFA to BSA ratios of 0.1:1 to 4:1 (2.5–100 µM C1-BODIPY-C12 and 5µM BSA). Non-cell
associated fluorescence was quenched with trypan blue as described [40]. Uptake was
measured at 485 nm excitation and 528 nm emission. The level of C1-BODIPY-C12
transported into the cell was calculated by conversion of the relative fluorescence units
(RFU) to concentration of C1-BODIPY-C12 calculated from a standard curve generated for
each lot of ligand. These experiments allowed the apparent KT and maximal rate (Vmax) of
C1-BODIPY-C12 transport to be defined. The experiments were repeated three times in
triplicate for each cell type and then the data was analyzed using Prism® 5.0 software.
Kinetics of transport for BODIPY-FL-C5 and BODIPY-FL-C16 were defined in a similar
manner.
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To assess expression of FATP1, FATP2 and FATP4, the major FATPs involved in fatty acid
transport, we employed western blotting using commercial antibodies coupled with the
appropriate secondary antibodies for detection using a LiCor Odyssey system (LI-COR
Biosciences, Lincoln, NE, USA). Cells were grown in T25 flasks, scraped and lysed in
protein extraction buffer (containing 150 mM NaCl, 50 mM Tris, 5 mM EDTA, 30 mM
Na2H2P2O7, 50 mM NaF, 1% Triton X-100, 1 mM PMSF, 1% Na3VO4 and 1X complete
EDTA free protease inhibitor) at 4°C with shaking for 30 min. To detect the FATP of
interest, 30 µg protein from a cleared lysate was separated by sodium dodecyl sulfatepolyacrylamide electrophoresis (SDS-PAGE), transferred to nitrocellulose membrane and
then incubated simultaneously with primary antibodies against β-actin (Sigma-Aldrich, St.
Louis, MO, USA) and the appropriate FATP antibody. Anti-FATP2 was purchased from
Abcam (Cambridge, MA, USA). FATP1 and FATP4 antibodies were from Santa Cruz
Biotechnologies (Santa Cruz, CA, USA). Protein quantification was performed with the
Odyssey system software.
2.5 Evaluation of Fatty Acid Transport Inhibition in Selected Cell Lines
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Caco-2 cells were plated in basal seeding medium and differentiated as detailed above.
HepG2 cells were cultured in EMEM (Eagle’s minimum essential media) and INS-1E cells
in RPMI 1640. Differentiated adipocytes were maintained in modified DMEM (Dulbecco's
Modified Eagle Medium) and 10% FBS. C2C12 cells were differentiated as detailed above.
After another 24 h, cells were serum-starved for 1 h in MEM (minimum essential media)
without phenol red prior to performing the BODIPY-FA transport assays [34]. In a standard
reaction, serum-free MEM was removed from the wells and 50 µL of the test compound in
MEM (MEM alone for controls) were added to each well and incubation was continued for
1 h. Then 50 µL of BODIPY-FA mixture (final concentrations 5µM BODIPY-FA; 5µM FFA
BSA; 1.97mM Trypan blue) were added to each well and the uptake was allowed to take
place for 15 min. The cell-associated fluorescence was measured in arbitrary units using
filter sets of 485nm excitation and 528 nm emission as detailed above. The inhibition of
fatty acid uptake activity using different chain lengths of BODIPY-FA was assessed using
different concentrations of selected compounds ranging from 0.001 to 500 µM. Ligand
competition curves were fit by nonlinear least-squares regression using one-site competition
and dose–response models in Prism software® (GraphPad Software, Inc., San Diego, CA) in
order to determine the compound concentration that reduced BODIPY fluorescence readout
by 50% (IC50). KT values were determined as above. RFU were converted to concentration
of BODIPY-FA in µM using a standard curve.
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To evaluate the mechanism of Lipofermata inhibition of fatty acid uptake, we determined
the kinetics of inhibition using 4 concentrations of C1-BODIPY-C12 (2.5 to 10.0 µM) and 11
concentrations of Lipofermata (1.25 – 20 µM). For these experiments, a BioTek Synergy
Plate reader equipped with microinjectors was used to distribute the Lipofermata at the
appropriate concentration and then the substrate C1-BODIPY-C12 was added to determine
initial rates of uptake over 90 seconds. The resulting rates were analyzed using the enzyme
kinetics module of SigmaPlot® 12.0 (Systat Software, Inc., San jose, CA, USA) to
determine the best fit model of inhibition.
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To assess fatty acid-mediated cell death, palmitic acid (PA) was added to cells after
conjugation with fatty acid free BSA to give the desired concentration of PA. Briefly,
palmitate was dissolved in absolute ethanol at a stock concentration of 50 mM and diluted
with the appropriate concentration of serum free BSA to maintain a ratio of 2.5:1 fatty
acid:BSA upon dilution in culture medium. For PA treatment HepG2 cells were routinely
seeded in 96-well plates at a density of 8 × 104 cells/well. After overnight attachment of the
cells, the culture medium was replaced by fresh MEM with 10% FBS with or without
various concentrations of PA-BSA alone or with Lipofermata at the desired concentration
for 24h then total intracellular lipid content was evaluated by Nile Red staining and the
extent of apoptosis by DAPI staining (detailed below). Similarly, INS-1E cells were seeded
in 96-well black/clear plates at a density of 2 × 105 cells/well and then incubated for 96 h
prior to PA and/or Lipofermata treatment for 24h.
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To visualize intracellular lipid droplets, the HepG2 cells or INS-1E cells were stained with
30 µg/ml Nile Red (NR) in DMSO in the dark for 30 min at 37°C, 5% CO2. Fluorescent
microscopic images (40×) were acquired using an Olympus IX-81 microscope. For
quantification, cell-associated fluorescence after Nile red staining was recorded with
excitation at 485/20 nm and emission at 590/35 nm spectral filter using the BioTek Synergy
Plate reader. Data was expressed as relative fluorescence units (RFU) per 1 × 106 cells and
presented as the mean of three experiments assayed in triplicate.
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To assess nuclear integrity live cells were stained with 5 µg/ml DAPI (4’,6-diamidino-2phenylindole dihydrochloride (Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37°C ,
5% CO2 and imaged at 40× magnification using an Olympus IX 81 fluorescence microscope
[41, 42]. Apoptosis was quantified by measuring in arbitrary units the cell-associated DAPI
fluorescence with filter sets of 360 nm excitation and 460 nm emission in the BioTek
Synergy Plate reader. Data were expressed as RFU per 1 × 106 cells and given as the mean
of three experiments assayed in triplicate.
2.7 Assessment of ROS production, ER stress and apoptotic protein expression
The ROS-Glo™ Assay (Promega Inc. Madison, WI, USA) was used to measure the level of
hydrogen peroxide (H2O2) directly in cell culture according to the manufacturer’s
recommendations. Glutathione (GSH) depletion was evaluated using the GSH Glo™
Glutathione Assay (Promega, Madison, WI, USA) according to manufacturer’s protocol.

Author Manuscript

BiP, CHOP or caspase 3 expression was assessed by western blotting as described above for
the FATPs (section 2.4). To detect BIP or caspase 3, 30 µg protein from a cleared lysate was
separated by sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE),
transferred to nitrocellulose membrane and then incubated simultaneously with primary
antibodies against β-actin (Sigma-Aldrich, St. Louis, MO, USA) and the antibody of
interest. In the case of CHOP, 60 µg lysate protein was used per sample. The rabbit
polyclonal antibody against caspase 3, BIP or the mouse polyclonal antibody against CHOP
protein were purchased from Cell Signaling Technology (Beverly, MA, USA). Protein
quantification was performed with the Odyssey system software.
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2.8 Assessment of uptake inhibition in mice
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C57BL/6 male mice (11 weeks of age) were obtained from Jackson Laboratories 1 week
prior to experimentation. Animals were housed in the AAALAC approved facility at the
University of Nebraska – Lincoln (UNL) in ventilated cages at 22° C with a 14/10 h day/
night cycle and were allowed free access to water and standard laboratory chow (2016
Teklad Global 16% Protein Rodent Diet (Harlan Laboratories, Indianapolis, IN, USA)). All
animal studies were reviewed and approved by the Institutional Animal Care and Use
Committee of UNL.
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To assess inhibition of fatty acid uptake, groups of mice (4 mice per treatment per time point
per experiment, 8 total) were fasted 12 h and then treated with 300mg/kg of lipofermata in
flaxseed oil. Controls received a vehicle consisted of flaxseed oil alone. To inhibit
lipoprotein lipase-dependent systemic fatty acid uptake, mice were injected with 500mg/kg
of tyloxapol in PBS by intraperitoneal injection prior to gavage with either Lipofermata or
vehicle. One hour after lipofermata administration, mice were given a bolus of flaxseed oil
containing 500mg/kg of 13C18-oleate (Sigma-Aldrich, St. Louis, MO, USA). At the desired
times after oleate administration (0.5, 2 and 6 h), animals were sacrificed, blood was
collected via cardiac puncture in EDTA-treated tubes, and plasma was prepared.
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To assess absorption of 13C18-oleate, plasma (25 µl) was extracted by the method of F olch
et al [43] in the presence of 0.05% butylated hydroxytoluene. Nonadecanoic acid (10 µg)
was added as an internal standard. Methyl ester formation was carried out using 1% sulfuric
acid in methanol and toluene at 50°C overnight. Samples were analyzed using an Agilent
7890A gas chromatography unit linked to an Agilent 5975C VL MSD (mass selective
detector) (Agilent, Palo Alto, CA, USA) using electron impact ionization. GC was
performed using an Agilent CP7421 Select FAME column, 200 m × 275 m × 0.25 m.
Samples (1 µl) were injected in a splitless mode with selective ion monitoring (SIM) of m/z
296 for the methyl ester of endogenous 12C oleate and m/z 314 for the methyl ester of 13C18
oleate, using 100ms dwell time per ion.
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To assess absorption of Lipofermata, 40 µl of acetonitrile containing 11 ng of an internal
standard (a closely related compound analogue) was mixed with 20 µl plasma. The sample
was mixed, 40 µl 0.1% trifluoroacetic acid (TFA) in water was added, and the sample was
gently vortexed for 5min. The samples were then centrifuged at 13,000 rpm for 5 min to
remove protein and the supernatants were analyzed using LC/MS-MS. For HPLC analysis,
two mobile phases used were mobile phase A containing 5/95/0.1 acetonitrile/deionized
water/formic acid (vol/vol) and mobile phase B containing 95/5/0.1 (vol/vol) acetonitrile/
deionized water/formic acid. Compounds were separated on a Phenomenex Gemini C18 2.1
× 50 mm, 5 µm column (Phenomenex, Torrance, CA., USA) at 40° C with a linear gradient
at 0.35 mL/min, and a 5 µl injection volume. The mobile phase was held at 20% B for 1 min,
increased linearly to 95% B over 3 min., held at 95% B for 2 min., and then re-equilibrated
at 20% B for 4 min. For all compounds the time, entrance potential, and cell exit potential
were set to 200 msec, 6 and 6 respectively. For CB16.2, q1 and q3 were set to 359.96 and
121.1 respectively while the declustering potential (dp) and collision energy (ce) were set to
47 and 34 respectively. For the internal standard, q1 and q3 were set to 287.19 and 120.87
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respectively while the dp and ce were set to 35 and 26 respectively. The amount of
lipofermata present in the blood was determined using a standard curve obtained using
known concentrations of lipofermata and the internal standard (0.09 to 3.3ng/µl).
2.9 Statistical analysis
A minimum of 3 experiments, each assayed in triplicate, were used for statistical
comparison as stated within the legends to the figures. Data were compared using JMP v11
analysis software (SAS Inst., Inc., Cary, NC, USA). Significance of difference was
determined using ANOVA, Student's paired t distribution, or bivariate fit Y by X. Values
were considered statistically significant at p <0.05. TIBCO Spotfire version 5.5.0 software
(TIBCO Spotfire, Boston, MA, USA) was used to study structural relatedness.
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3. Results
3.1 Characterization of FA transport in INS-1E, C2C12 and Human Adipocytes
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To assess the efficacy of fatty acid transport inhibition by Lipofermata we initially employed
HepG2 and Caco-2 cells, which are models for liver and intestinal epithelia, respectively
[34]. However, fatty acid trafficking between organs has at least three additional targets that
contribute to metabolic homeostasis including skeletal muscle, pancreas and adipocytes.
Therefore, we selected three cell lines to model these organs, including: murine C2C12
myocytes, which form tubules in culture characteristic of myoblasts and, which import and
metabolize exogenous fatty acids [44, 45]; rat INS-1E cells, which are a clonal ß-cell line
that release insulin in response to glucose and are known to be susceptible to fatty acidmediated apoptosis [37, 46, 47]; and primary human adipocytes. For each of these cell lines
a live cell assay was employed to monitor the transport of fatty acids in real-time over 5
minutes using the fluorescent long-chain fatty acid analogue C1- BODIPY-C12 as previously
developed in our laboratory [39]. The transport of the fluorescent long-chain fatty acid C1BODIPYC12 in these cells lines follows typical Michaelis–Menten kinetics (Fig. 2 and
Table 1). INS-1E cells were the least efficient in fatty acid transport. The Vmax value was
more than 32-fold lower than that defined for adipocytes, which had the highest rates of
fatty acid transport. KT values were more similar between cell lines ranging from 18.1 µM
for INS-1E cells to 43.7 µM for adipocytes, indicating the affinity of uptake between cell
lines was more similar than the capacity to accumulate the lipid product.

Author Manuscript

Since fatty acid transport activity has been attributed to FATP1, FATP2, and FATP4, we
compared the expression level of each in the various cell lines using western blotting. As
shown in Fig. 3, FATP2 and FATP4 are strongly expressed in Caco-2 and HepG2. INS-1E
cells also strongly express FATP2, while FATP1 and 4 were not detected. In contrast,
C2C12 myocytes primarily expressed FATP1 and, to a more minor extent, FATP2 and
FATP4. Human adipocytes primarily express FATP1 and, as expected, were more resistant
to the FATP2 inhibitor. These data are similar to our previous results that estimated gene
expression in HepG2 and Caco-2 cells [19] and to information available in the human
protein database for cells and tissues (http://www.proteinatlas.org/).
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We further assessed Lipofermata-dependent inhibition of fatty acid uptake to determine the
mechanism of inhibition using a standard kinetics approach. For these experiments we
employed HepG2 cells and varied both C1-BODIPY-C12 and Lipofermata concentrations
(Fig. 4). Since the structure of Lipofermata is very different from that of a long chain fatty
acid, we expected the inhibition to be non-competitive and as seen in Fig. 4, this proved to
be the case.
3.2 Evaluation of the inhibition of fatty acid uptake by structural analogues of Lipofermata

Author Manuscript

The CB16 family of compounds was identified as fatty acid transport inhibitors in a high
throughput screening of humanized yeast expressing human FATP2 [34]. Only three
structurally related molecules were examined in our initial report. Among these CB16.2 (5bromo-5'-phenyl-3'H-spiro[indole-3,2'-[1,3,4]thiadiazol]-2(1H)-one) now called
Lipofermata had the highest specificity and lowest IC50. In the present work, we examined
additional analogues to assess structural features required for compound activity (Table 2).
These analogues were evaluated in our set of five targeted cell lines to evaluate the effects of
structural variations compared with the Lipofermata as the parent compound and to estimate
the IC50 for transport inhibition.
Lipofermata inhibited C1-BODIPY-C12 transport into C2C12, INS-1E, Caco-2 and HepG2
cells at comparable levels yielding sigmoidal dose-response curves with IC50s in the low
micromolar range (Table 2). Primary human adipocytes were more resistant to this
compound and yielded IC50 values about 10-fold higher.
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Additional analogues were tested that allowed us to assess the contribution of four different
regions of the molecule to activity (Table 2). The simplest change was the addition of a
methyl group to R3 on the nitrogen of the spiro-indole moiety to give CB16.4 (5-bromo-1methyl-5'-phenyl-3'H-spiro[indole-3,2'-[1,3,4]thiadiazol]-2(1H)-one). This change caused a
slight increase in the IC50 for Caco-2, HepG2 and C2C12 cells, but had no effect in
adipocytes or INS-1E cells. In CB16.3 two changes in the core structure were effected to
substitute an ethyl group in place of the bromine and a hydroxyl group on the phenyl ring to
give 5-ethyl-5'-(2-hydroxyphenyl)-3'H-spiro [indole −3,2'- [1,3,4]thiadiazol]-2(1H)-one.
Again, these changes increased the IC50s for Caco-2, HepG2 and C2C12 cells 2- to 3-fold
but had no effect on the IC50 for adipocytes or INS-1E cells. Conversion of the phenyl group
to a napthyl and removal of the bromine generated CB16.5 (1-methyl-5'-(1-naphthyl)-3'Hspiro[indole-3,2'-[1,3,4]thiadiazol]-2(1H)-one). These changes substantially increased the
IC50 for Caco-2 (9.2-fold), HepG2 (14.8-fold), C2C12 (5.4-fold) and INS-1E (2.4 fold) cells
but had a less severe effect on adipocytes, increasing the IC50 by about 35 percent. Removal
of the phenyl ring (R1) and replacement of the spiro[indole-3,2'-[1,3,4]thiadiazol with
spiro[1,3-dioxolane-2,3'-indol] generated CB16.6 (5'-bromo-7’-methylspiro[1,3dioxolane-2,3'-indol]-2'(1’H)-one, a compound that was ineffective in adipocytes, C2C12
and INS-1E cells. An IC50 could be estimated for Caco-2 and HepG2 cells for this
compound but was increased 87- and 70-fold respectively. Of the compounds tested in this
structural class, Lipofermata remains the most effective in inhibiting long chain fatty acid
transport as evaluated using the fluorescent analogue C1-BODIPY-C12. Recently, we
prepared a small series of analogues to further interrogate the 5-position of the spiro-
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indolinone. Preliminary data in HepG2 cells indicate in some cases comparable inhibition
activity. As shown in Fig.5, ether substituents such as CB16.106 bearing a trifluoromethoxy
and CB16.107, containing a methoxy substituent had IC50 values below 5 µM. An analogue
bearing an electron withdrawing nitro group (CB16.103) was less effective at this position
(IC50 = 14 µM); however, both methyl and ethyl substituent (CB16.101 and CB16.105,
respectively) had activity within two-three fold of parent CB16.2 in the HepG2 cells. Lack
of a substituent at the C(5) position (CB16.104) or a simple hydroxy (CB16.108) were
significantly deleterious on inhibitory activity (IC50 = 40 µM), thus highlighting the
importance of this substituent as a key contributor to the overall pharmacore for inhibitory
activity. Lastly, the isatin of CB16.2 was tested as a control to eliminate any potential
contribution from trace starting material or hydrolytically derived by-product. Gratifyingly,
in this experiment the CB16.2 isatin was found to have no effect in several cell lines,
suggesting the inhibitory effects are specific to the 5'-phenyl-3'H-spiro[indoline-3,2'[1,3,4]thiadiazol]-2-one core. Collectively, the robust SAR observed from C(5) bromine
replacements, minimum pharmacophore/deletion studies, and control compounds further
supports a specific interaction and role for CB16.2 in affecting long chain fatty acid
transport.
3.3 Assessment of transport and Lipofermata-dependent inhibition by fatty acid analogues
with different chain lengths

Author Manuscript

C1-BODIPY-C12 is a long chain fatty acid analogue and uptake of this compound is
efficiently inhibited by Lipofermata ([34] and herein). To evaluate the effect of this
compound on the transport of fatty acids with different chain lengths we employed the
fluorescent medium chain fatty acid analogue BODIPY-FL-C5 and the very long chain fatty
acid analogue BODIPY-FL-C16 in Caco-2 and HepG2 cells. The transport of the medium
chain fatty acid analogue was not saturable and uptake was consistent with a proteinindependent mechanism (data not shown). This was expected since medium chain fatty acids
(C6-C10) traverse membranes by simple diffusion [48, 49]. By contrast the uptake of the
very long chain fatty acid analogue BODIPY-FL-C16 was saturable, displayed typical
Michaelis-Menten kinetics and yielded Vmax values of 0.81 ± 0.2 µmol/min/106 cells for
Caco-2 and 2.2 ± 0.67 µmol/min/106 cells for HepG2. KT values for both cell lines were
comparable (16.4 ± 7.1 µM and 37.41 ± 15.52 µM for Caco-2 and HepG2 cells,
respectively) (Fig. 6A).
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Lipofermata was also effective in inhibiting BODIPY-FL-C16 uptake in Caco-2 and HepG2
cells (Fig. 6B-6C), yielding IC50 values of 6 µM and 2.3 µM respectively. As expected,
Lipofermata had no effect on the uptake of the medium-chain analogue BODIPY-FL-C5 in
either cell type since medium chain fatty acid uptake occurs by simple diffusion (Fig.
6B-6C) [48, 49].
3.4 Lipofermata protects against palmitate induced lipid droplet accumulation and toxicity
Lipotoxicity is a term used to describe the detrimental effects of lipids on cells in culture and
obesity-associated organ dysfunction and failure [50, 51]. To investigate whether
Lipofermata was effective in protecting against cellular toxicity caused by excessive fatty
acid uptake and accumulation, we incubated HepG2 or INS-1E cells with the saturated fatty
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acid, palmitic acid (PA) in the absence or presence of Lipofermata. The cells were cultured
with different concentrations of PA for 24h. As a control, cells were treated with equimolar
concentrations of FFA-BSA alone. Lipid droplet accumulation was dependent upon the
addition of PA in a dose-dependent manner as observed using confocal microscopic imaging
(Figs. 7A for HepG2 and Fig. 8A for INS-1E cells, respectively) and quantitative
fluorescence measurements of treated cells stained with the lipophilic dye Nile Red (Figs.
7B for HepG2 and Fig. 8B for INS-1E cells, respectively. Treatment of either cell type with
PA and Lipofermata at concentrations ranging from 5–50 µM significantly attenuated lipid
droplet accumulation.
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To assess apoptosis of HepG2 or INS-1E cells following incubation with PA, nuclear
integrity was assessed using DAPI staining of live cells. Increased DAPI staining is
indicative of processes that lead to apoptotic cell death [41, 42]. The levels of apoptosis
were not significantly different for those grown in the presence of ≤ 0.25 mM PA compared
with control cells, while cells grown in the presence of 1 mM PA resulted in extensive loss
of cell viability (Figs. 7C and 7D for HepG2 and Figs. 8C and 8D for INS-1E, respectively).
Lipofermata attenuated the loss of nuclear integrity induced by PA in each cell line in a
dose-dependent manner.
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PA induced cellular toxicity is characterized by a series of events including increased
oxidative stress, ER dysfunction and initiation of the apoptotic death program [3, 47, 52].
Since we predict Lipofermata protects against lipotoxicity by preventing fatty acid uptake, it
should avert activation of these pathways leading to cell death. As shown in Figs. 9A and
9B, PA treatment increased the level of ROS and reduced the level of the antioxidant
glutathione (GSH) in both HepG2 and INS-1E cells and, as expected, lipofermata was
protective. Further, Lipofermata treatment prevented the PA-induced increase in expression
of the ER chaperone BiP in both HepG2, fig 10A and INS-1E,fig 10C; limited the increase
in expression of the cell death transcription factor CHOP (Figs. 10B and 10D, for HepG2
and INS-1E cells, respectively) and the caspase-3 cysteine protease (Figs. 11). Thus,
Lipofermata effectively protects cells against lipotoxic cellular dysfunction at multiple
levels.
3.5 Prevention of lipid absorption in vivo
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To evaluate whether Lipofermata [1] would prevent or attenuate fatty acid absorption in
vivo, as predicted and [2] to estimate the compound’s absorption into the circulatory system,
we conducted proof of concept tests in mice. A single dose of Lipofermata (300mg/kg)
given by gavage reduced plasma levels of 13C-oleate by 57% 2 hours after oleate
administration and by 74% 6 hours post-administration (Fig. 12A). The compound was
absorbed to a significant extent and could be detected within 30 min of treatment (1.58 ±
0.03 ng/µl plasma; Fig. 12B). The plasma levels were stable at 2 hrs (1.52 ± 0.41 ng/µl
plasma) but were reduced by about 50% at 6 hrs (0.94 ± 0.22 ng/µl plasma). These results
confirm Lipofermata prevents fatty acid uptake across the intestinal epithelium and suggests
it may enter the blood stream to confer inhibitory affects on fatty acid uptake in other
tissues.
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4. Discussion
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In previous work, we identified several families of small molecules that attenuated the
uptake of fatty acids into mammalian cells using a high throughput screening approach.
Such inhibitors are of use in dissecting mechanistic information concerning FATPdependent fatty acid transport and as attenuators of lipotoxic disease progression. While
FATP1 and FATP4 inhibitors have also been reported, these were directed against the acylCoA synthetase activity of these FATPs and not the transport activity [53–55]. The
compounds we identified were effective in disrupting FATP2-specific fatty acid transport in
humanized yeast and also attenuated fatty acid uptake using cell lines that are models for
hepatocytes, intestinal epithelial cells and adipocytes (murine) [34]. In the present work we
focused on one compound, Lipofermata, previously called CB16.2, which had the highest
efficacy, and several of its structural derivatives. Lipofermata is highly effective in
inhibiting fatty acid uptake and extends our previous findings to demonstrate this
compounds prevents lipid accumulation in cells that are models for myocytes (C2C12) and
pancreatic ß-cells (INS-1E). The compound is less effective in inhibiting fatty acid uptake
into human adipocytes, the preferred lipid storage site. Lipofermata prevents lipid droplet
accumulation and the cytotoxic effects of fatty acids in HepG2 and INS-1E cells. These data
support the conclusion that Lipofermata, in addition to attenuating fatty acid uptake, also has
potential to protect cells from lipotoxic dysfunction and death.

Author Manuscript
Author Manuscript

Lipofermata inhibits long chain fatty acid uptake into cells [34]. The fluorescent fatty acid
analogue C1-BODIPY-C12 is a useful surrogate for native fatty acids that is easily assayed,
imported in a FATP-dependent manner, and is metabolized by cells and becomes integrated
into complex lipids [39]. Related fluorescent fatty analogues are surrogates for medium
chain fatty acids, BODIPY-FL-C5, and very long chain fatty acids, BODIPY-FL-C16.
Medium chain fatty acids enter cells largely by a diffusional process that does not require a
protein transporter. The uptake of BODIPY-FL-C5 displayed characteristics of simple
diffusion and thus is consistent with these earlier studies. Lipofermata had no effect in
attenuating medium chain fatty acid uptake in the cell types tested showing this compound is
ineffective for this class of fatty acids. In contrast, the very long chain fatty acid analogue
BODIPY-FL-C16 was imported into HepG2 and Caco-2 cells yielding saturable dose
response curves indicative of a protein mediated process in both HepG2 and Caco-2 cells.
Lipofermata inhibited uptake of BODIPY-FL-C16 with IC50s in the micromolar range that
are consistent with values obtained for C1-BODIPY-C12. We conclude Lipofermata
functions as an effective inhibitor of uptake of long and very long chain fatty acids. These
data correlate with our previous studies using FATP2 overexpressing and knock-down cell
lines treated with fatty acids labeled with stable isotopes, which demonstrated this protein
mediates fatty acid uptake by the process of vectorial acylation [56, 57].
Additional Lipofermata derivatives were tested to [1] determine whether they had increased
efficacy and [2] to define structural features that contributed to its activity in attenuating
fatty acid uptake. The inhibitory potency of Lipofermata was not increased in any of these
structural derivatives. However, several changes in the molecule were informative regarding
required components of the molecule. Substitution of the 1,3,4 thiadiazol with a 1,3
dioxolane ring essentially eliminated compound efficacy. While not as severe, substitution
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of a napthyl ring for the phenyl at R1 also substantially reduced compound activity.
Additional derivatives of Lipofermata are currently being synthesized to define and improve
efficacy of novel FATP2 inhibitors.
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On the basis of these findings, we suspected Lipofermata would also be useful to attenuate
cellular and organ lipotoxicity, which leads to disease. The saturated fatty acid PA is a major
component of the western diet and high levels of dietary intake of this fatty acid are
correlated with various life style diseases including Type 2 diabetes and NAFLD [11, 58–
60]. Further, PA has been shown to induce apoptosis in pancreatic β-cell lines as well as in
hepatocytes [61, 62]. HepG2 and INS-1E cells grown in the presence of PA develop
intracellular lipid droplets and display characteristics of apoptotic cell death. Lipofermata
treatment was effective in blocking both the accumulation of lipid droplets and apoptotic
cell death in a dose-dependent manner. To confirm what we suspected was lipoapoptosis
various markers of PA-induced cellular dysfunction were assessed (i.e. ROS, GSH, BiP,
CHOP and caspase-3 levels). In every case Lipofermata was able to prevent toxicity and
activation of the cell death program. Chronic exposure of both liver and ß-cells to high
levels of saturated fatty acids has been shown to induce apoptosis and disrupt cellular
function thereby contributing to the pathogenesis of fatty liver disease [4, 15, 63] and type 2
diabetes [64–66]. This work clearly demonstrates Lipofermata, at relatively low
concentrations (5–50 µM), promotes survival of HepG2 and INS-1E cells and protects
against PA-induced lipotoxicity. Further, these findings suggest that this compound may
have therapeutic potential in protecting ß-cells against lipotoxicity caused by diets high in
saturated fat.
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These studies are consistent with FATP2 as the target for Lipofermata. This compound
inhibits FATP2-specific long chain fatty acid transport in humanized yeast cells, and in
HepG2 and INS-1E cells is protective against saturated fatty acid-induced lipotoxicity and
apoptosis. In contrast the compound displayed poor efficacy in adipocytes, which by
comparison with the other cell lines, poorly express FATP1 and 4 and do not express
FATP2. The precise mechanism underlying the protective role of Lipofermata in the
progression of lipotoxicity is not well understood. This work demonstrates it functions as a
noncompetitive inhibitor of fatty acid uptake, the primary metabolic target of its activity.
Attenuation of the uptake of saturated fatty acids by Lipofermata, clearly demonstrates its
potential as a therapeutic to address lipotoxic disease.
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One of the predicted uses of lipofermata is as an inhibitor of fatty acid absorption for use in
mechanistic studies in animals and, perhaps eventually, as a therapeutic. In the early animal
trials reported here, Lipofermata inhibited fatty acid uptake across the gut in a time
dependent manner. The compound was detectable in plasma but from the methods employed
we could not determine impact on tissue fatty acid trafficking due to co-treatment with
Tyloxapol. To our knowledge, there are no other compounds that inhibit fatty acid
absorption in the same manner. Orlistat is an approved drug for use in inhibiting fat
absorption [67]. It functions by inhibiting pancreatic lipase and thus triglyceride breakdown
[68]. In this case, since the fatty acids are not released from the complex lipid, they cannot
be absorbed. We envision Lipofermata as a partner in this process, which will further inhibit
free fatty acid uptake.
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In summary, these results demonstrate that the treatment of five different cell line with
physiologic concentrations of Lipofermata blocks fatty acid transport without impacting
other cellular functions, supporting the proposed neutral properties of this compound. This
fatty acid transport inhibitor is most effective in cell lines subject to the toxic effects of high
levels of saturated fatty acids but is less effective in fat cells, which store fatty acids as
triglycerides. These properties are expected to be useful to partition potentially toxic fatty
acids away from cells where they may cause dysfunction leading to NAFLD, heart failure
and insulin resistant diabetes.
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Acsl

long chain acyl-CoA synthetase

BiP

binding immunoglobulin protein

BSA

bovine serum albumin

C1-BODIPY-C12

4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic
acid

CHOP

CCAAT/-enhancer-binding protein homologous protein

DAPI

4’,6-diamidino-2-phenylindole

DMSO

dimethyl sulfoxide

EDTA

ethylenediaminetetraacetic acid

ELSD

evaporative light scattering detection

FA

fatty acid

FFA

free fatty acid

FATP2

fatty acid transport protein 2, also known as Slc27a2

GC/MS

gas chromatography/mass spectrometry

GSH

glutathione

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)

HPLC

high performance liquid chromatography

LCFA

long chain fatty acid

LC/MS

liquid chromatography/mass spectrometry

Lipofermata

CB16.2, 5'-bromo-5-phenyl-spiro[3H-1,3,4-thiadiazole-2,3'indoline]-2'-one

MEM

minimum essential media
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MUFA

monounsaturated fatty acid

NAFLD

non-alcoholic fatty liver disease

NR

Nile Red

PA

palmitic acid

PMSF

phenylmethylsulfonyl fluoride

ROS

reactive oxygen species

RFU

relative fluorescence units

RP-HPLC

reverse phase high performance liquid chromatography

SFA

saturated fatty acid

T2D

type II diabetes mellitus

TFA

trifluoroacetic acid

UFA

unsaturated fatty acid

VLCFA

very long chain fatty acid
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Fig. 1.

Synthesis scheme for Lipofermata and structural derivatives. For details, see section 2.2.
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Kinetics of C1-BODIPY-C12 uptake in targeted cell lines. Fatty acid transport was measured
in real-time using C1-BODIPY-C12 at 5 sec intervals for 5 min. The linear rate of uptake for
each concentration of fluorescent fatty acid was determined using initial values from 30 to
90 sec and plotted as µmole/min/106 cells as indicated. The error bars represent the standard
error of the mean from three independent experiments.
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Fig. 3.

Expression of FATP proteins in various cell lines. Western blots employing antibodies
against FATP1, 2 or 4 were used to measure the expression of each protein in the targeted
cell lines as shown. (A) Representative western blots comparing expression of the relevant
FATP compared with ß-actin used as a loading control. (B) Results were quantified using
Odyssey imaging software (Li-COR, Lincoln, NE, USA). The bar height indicates the mean
of three experiments assayed in triplicate. Error bars indicate standard deviation from the
experimental mean.
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Fig. 4.

Kinetic assessment of Lipofermata inhibition of fatty acid uptake in HepG2 cells. The fatty
acid analogue C1-BODIPY-C12 was used to evaluate the mechanism of Lipofermata
inhibition of fatty acid transport. The inserted legend indicates the concentrations in µM of
Lipofermata used to generate the lines. Data points are the mean and the error bars indicate
the standard deviation. As shown, the data were best fit to a noncompetitive inhibition
model. Analysis was performed using SigmaPlot 12 enzyme kinetics module.
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Fig. 5.

Structure activity analysis of CB16.2 analogues. As shown, seven analogues and the isatin,
starting material for compound synthesis, were tested for inhibition of fatty acid uptake in
the standard assay employing C1-BODIPY-C12.
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Fig. 6.

Kinetics of BODIPY-FL-C5 and -C16 uptake in HepG2 and Caco-2 cells and inhibition by
Lipofermata. (A) Fatty acid transport rates were measured in real-time using BODIPY-FL
C16 at 5 sec intervals for 5 min in HepG2 and Caco-2 cells as indicated. The linear rate of
uptake was determined using initial values from 30 to 90 sec at each ligand concentration.
The error bars represent the standard error of the mean from three independent experiments.
Inhibition of BODIPY-FL C16 but not BODIPY- FL C5 uptake by Lipofermata occurred in
a dose responsive manner in (B) HepG2 and (C) Caco-2 cells, respectively.
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Inhibition of lipid droplet accumulation and apoptosis by Lipofermata in HepG2 cells.
HepG2 cells were incubated with 100 or 500 µM palmitate (PA) or with a combination of
PA and Lipofermata at varying concentrations as indicated. After 24 hrs intracellular lipid
droplets were evaluated using Nile Red staining and apoptosis was assessed by staining with
DAPI (4’, 6-diamidino-2-phenylindole dihydrochloride). (A) and (C) Confocal microscopic
images (40X magnification) shown are representative of Nile Red or DAPI stained cells,
respectively. Quantification of fluorescence accumulation for (B) NR or (D) DAPI,
expressed as RFU/106 cells (y-axis). Concentrations of PA were as indicated on the x-axis;
white bars indicate no Lipofermata treatment, light gray bars 5µM, dark gray bars 10 µM
and black bars 50 µM. The bar height indicates the mean of three experiments assayed in
triplicate. Error bars indicate standard deviation from the experimental mean. The data was
compared using ANOVA (JMP 11.0) for Lipofermata versus PA. Levels not connected by
the same letter are significantly different.

Author Manuscript
Biochem Pharmacol. Author manuscript; available in PMC 2016 November 01.

Ahowesso et al.

Page 27

Author Manuscript
Author Manuscript
Author Manuscript

Fig. 8.

Inhibition of lipid droplet accumulation and apoptosis by Lipofermata in INS-1E cells.
INS-1E cells were treated in exactly the same manner as HepG2 cell as shown in Fig. 7 (see
Fig. 7 legends for details).
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Prevention of oxidative stress by Lipofermata. The levels of ROS and GSH were measured
after treatment with PA with or without Lipofermata at the concentrations given. (A) HepG2
cells and (B) INS-1E cells. Bar height indicates the mean of 3 experiments. Data were
compared using 2-way ANOVA. Levels not connected by the same letter are significantly
different at p < 0.001 for each comparison, ROS or GSH versus PA.

Biochem Pharmacol. Author manuscript; available in PMC 2016 November 01.

Ahowesso et al.

Page 29

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Fig. 10.

Lipofermata prevents the induction of cell stress response proteins BiP and CHOP by PA
treatment in HepG2 and INS-1E cells. The ER chaperone BiP and the transcription factor
CHOP were quantified by western blotting. The colored figures are representative western
blots. Bar height indicates the mean ± SEM for BiP or CHOP as indicated in each of the cell
lines from 3 independent experiments. The expression levels were normalized to that of βactin (red bands). *p < 0.05 for comparison to controls without palmitate or Lipofermata; #p
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< 0.05 for compound and palmitate treated cells compared with cells treated with 500 µM
palmitate alone.
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Fig. 11.

Lipofermata prevents induction of caspase-3 protein expression in HepG2 or INS-1E cells
treated with palmitate. Cells were exposed to increasing concentrations of (A) palmitate, or
(B) to a combination of palmitate and Lipofermata, as indicated. After 24 h of incubation,
caspase-3 abundance was evaluated by Western blotting. The upper images are
representative western blots. In the lower bar graphs, bar height indicates the mean ± SEM
for caspase-3 of 3 experiments. The expression level of the caspase-3 (green bands) was
normalized to that of β-actin (red bands). *p < 0.05 for comparison to controls without
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palmitate or Lipofermata; #p < 0.05 for compound and palmitate treated cells compared with
cells treated with 500 µM palmitate alone.
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Fig. 12.

Inhibition of fatty acid absorption by Lipofermata in mice. Mice were dosed orally with 300
mg/kg Lipofermata for 1 h followed by 500mg/kg 13C-oleate and then plasma levels of
A)13C-oleate and B) Lipofermata were measured. Bar height indicates the mean for 8 mice ±
SE.
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Kinetic parameters of C1-BODIPY-C12 transport in different cell types
Vmax

KT

Cell Line

µmol/min/106 cells (SEa)

µM (SE)

INS-1E

17.1 ± 1.5

18.1 ± 4.3

C2C12

40.1 ± 1.9

20.9 ± 2.6

HuAdipo

559.2 ± 57.5

43.7 ± 9.7

Caco-2

63.5 ± 5.8

32.8 ± 7.1

HepG2

67.3 ± 6.6

40.1 ± 8.7

a

SD, Standard deviation of 3 experiments done in triplicate
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CB16.5

CB16.3

Name/Designation

R1

R2

Structural similarities and differences

HepG2

16.33±4.44

-CH3

6.09±1.00

14.64±4.30

9.40±2.22

2.74±0.90

IC50 µM (SEM)a

22.08±7.17

R4

-H

-H

R3

Caco2
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Inhibition of fatty acid transport by Lipofermata/CB16.2 and related compounds

27.54±5.99

30.24±6.41

39.34±9.34

Adipocytes

12.89±1.43

8.95±1.10

5.67±1.35

C2C12

4.75±0.62

3.80±0.46

4.65±1.56

INS-1E
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R1

R2

-H

-CH3

R3

R4

HepG2

532.00±250

56.70±8.83

191.20±94

40.00±12.95

IC50 µM (SEM)a

Data derived from log dose response curves analyzed using Prism 5.0. Values indicate the mean ± of three independent experiments.

a
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Name/Designation

Author Manuscript
Caco2

Not effective

53.19±16.39

Adipocytes

Not
Effective

30.67±3.76

C2C12

Not
Effective

11.27±3.46

INS-1E
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